NOS3 and congestive heart failure: The following findings emerge from this study: (i) Treatment with rosuvastatin 40 mg for 12 weeks in patients with chronic heart failure does not affect the ability of isolated HDL to change the phosphorylation of PKC-βII at Ser660 and the phosphorylation of eNOS at its activity regulating sites Ser1177 and Thr495 in cultured endothelial cells.